Cancer Tumor Profiling Market Anticipated To Witness Robust Growth, Surpassing $25.33 Billion By 2029

The Cancer Tumor Profiling Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Cancer Tumor Profiling Market Size and Its Estimated Growth Rate?
In recent times, there has been a swift expansion in the cancer tumor profiling market. The market is projected to surge from $13 billion in 2024 to approximately $14.99 billion in 2025, with a compound annual growth rate (CAGR) of 15.3%. Factors attributing to the growth during the historic period include the rise in cancer cases, progress in precision medicine initiatives and research partnerships, enhancements in cancer diagnosis and early detection methodologies, accessibility to a diverse array of targeted therapy choices, and favorable regulatory guidelines for cancer profiling examinations.

The market size for cancer tumor profiling is projected to experience swift expansion in the upcoming years. It is projected to escalate to $25.33 billion by 2029, with a compound annual growth rate (CAGR) of 14.0%. The growth during the forecast period is driven by factors such as the expansion of immunotherapy and immunoprofiling in the arena of cancer treatment, technological progression in liquid biopsy and non-invasive tumor profiling strategies, the use of single-cell sequencing for comprehensive tumor characterization, the broadening of cancer screening and early detection initiatives, and an elevated demand for rare and orphan cancer subtype profiling. The major trends witnessed during the forecast period are expected to be the incorporation of tumor profiling into customary clinical practice, advancements in multi-omics tactics, the employment of artificial intelligence (AI) and machine learning in data interpretation, the progression of personalized medicine and targeted therapy, and advancements in genomics and next-generation sequencing (NGS) technologies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6053

How Are Emerging Segments Shaping the Cancer Tumor Profiling Market Landscape?
The cancer tumor profiling market covered in this report is segmented -

1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies
3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types
4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

Subsegments:
1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer
3) By Colorectal Cancer: Colon Cancer, Rectal Cancer
4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer
5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma
6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer
7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)
8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors
9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer
10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

Which Growth Factors Are Influencing Cancer Tumor Profiling Market Expansion?
The global surge in cancer cases is anticipated to fuel the expansion of the cancer and tumor profiling market. Cancer is a condition where some body cells multiply uncontrollably and infiltrate other body parts. There is a growing need for cancer tumor profiling parallel to the increasing number of cancer cases, as this helps medical practitioners assess the intensity of the disease. For example, the American Cancer Society, a professional organization based in the United States, revealed that the country had detected 2 million new cancer cases in 2024, which was higher than the 1.9 million fresh cases registered in 2023. Consequently, the escalating rate of cancer globally stimulates the growth of the cancer and tumor profiling market.

Who Are the Dominant Players Across Different Cancer Tumor Profiling Market Segments?
Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

What Are the Latest Developing Trends in the Cancer Tumor Profiling Market?
The prevailing trend in the cancer and tumor profiling market has been observed to be the escalating activities related to research and development. Several prominent corporations working in the sphere of cancer and tumor profiling are prioritizing these activities with the aim to cater to consumer needs and to solidify their market standing. Illustratively, QIAGEN N.V, a Germany-based company known for innovating sample and assay technology for myriad applications such as applied testing, development of pharmaceuticals, molecular diagnostics, and academic study, has declared the attainment of Conformitè Europëenne (CE)-marking and the commencement of the commercial selling of the therascreen PIK3CA RGQ PCR Kit in Europe. This would function as an aid in pinpointing breast cancer patients exhibiting PIK3CA mutations. The therascreen PIK3CA test is a diagnostic procedure for detecting an activating mutation in the PIK3CA gene, specifically in the phosphatidyl 3-kinase catalytic subunit alpha, and it is the first to allow the application of DNA both from plasma samples and FFPE tissues.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Which Geographic Regions Are Expected to Dominate the Cancer Tumor Profiling Market in the Coming Years?
North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Cancer Tumor Profiling Market?
2. What is the CAGR expected in the Cancer Tumor Profiling Market?
3. What Are the Key Innovations Transforming the Cancer Tumor Profiling Industry?
4. Which Region Is Leading the Cancer Tumor Profiling Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.